Risk Factors Update Summary
- Increased the number of full-time employees from 11 to 13, indicating organizational growth.
- Commenced Phase 1 study for NXP900, with dose-escalation Phase 1a completed in April 2023.
- Announced Phase 1b for NXP900 expected to start in the first half of 2023.
- Collaboration with Mayo Clinic for an investigator-sponsored clinical trial in cholangiocarcinoma.
- Granted Orphan Drug Designation to NXP800 for the treatment of cholangiocarcinoma.
- Investigating the use of ARID1a mutations as a potential patient selection marker for various cancers.
- Transitioning from early development stages to becoming commercially viable, with accumulated deficit at $54 million.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1875558&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.